# Aeterna Zentaris GmbH

Type: Company

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/aeterna-zentaris-gmbh
Canonical HTML page: https://gethealthbrief.com/entity/aeterna-zentaris-gmbh

## Timeline

- **2026-03-05**: Strategic Update — COSCIENS announces cessation of funding for German subsidiaries and expected insolvency.
- **2026-02-15**: FDA Type C Meeting — Company meets with FDA to discuss disappointing DETECT trial results and pediatric path forward.
- **2025-11-10**: DETECT Trial Results — Phase 3 trial for Macrilen pediatric indication fails to meet primary endpoints.
- **2025-08-20**: Wuzhou Distribution Deal — COSCIENS signs distribution agreement with Wuzhou Drug International Trading Limited.

## Recent coverage (1 stories)

### COSCIENS Biopharma Abandons German Units Following Macrilen Pediatric Setback
2026-03-06 01:03:55 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

COSCIENS Biopharma Inc. (TSX: CSCI) has announced a strategic cessation of funding for its German subsidiaries, Aeterna Zentaris GmbH and Zentaris IVF GmbH, effectively triggering an insolvency process. This decision follows a critical failure in the Phase 3 DETECT trial for Macrilen’s pediatric indication and a subsequent setback in FDA negotiations.
Full story: https://gethealthbrief.com/story/cosciens-biopharma-german-subsidiaries-insolvency-macrilen

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.